加载中
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
前收盘价
US$19.52
−US$0.98 · -4.78%
盘中时间采用ET。市场数据可能有所延迟。
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
日内区间
当前US$19.52
52周区间
当前US$19.52
盘中时间采用ET。市场数据可能有所延迟。
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
日内区间
当前US$19.52
52周区间
当前US$19.52
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1679.5万 USD | — | — | — | — |
| 销货成本 | 936.5万 USD | — | — | — | — |
| 毛利 | 743万 USD | — | — | — | — |
| 研究与开发 | 122.8万 USD | 117.94万 USD | 257.94万 USD | 39.17万 USD | 20.9万 USD |
| 销售、一般及管理费用 | 3707.6万 USD | 639.2万 USD | 428.29万 USD | 192.64万 USD | 62.99万 USD |
| 营业费用 | 3986万 USD | 757.14万 USD | 686.23万 USD | 231.82万 USD | 83.9万 USD |
| 利息收入 | 5000 USD | — | — | — | — |
| 利息支出 | 301.2万 USD | 78.64万 USD | 51.85万 USD | 14.04万 USD | 253 USD |
| 折旧和摊销 | 228.5万 USD | — | — | — | — |
| 营业利润 | −3243万 USD | −757.14万 USD | −686.23万 USD | −231.82万 USD | −83.9万 USD |
| 净利润 | −4331.9万 USD | −795.53万 USD | −738.08万 USD | −245.86万 USD | −59.54万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
